Bristol-Myers Squibb Company (BMY) 58.70 $BMY
Inovio-Roche End Deal for Development of Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:26PM CST
Inovio Pharmaceuticals, Inc. (INO) announced the termination of its agreement with Roche for the co-development of Inovio's prostate cancer candidate, INO-5150.
INO: 9.86 (-0.07), AZN: 73.98 (+1.48), BMY: 58.70 (+0.27)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Roche's (RHHBY) Avastin Label Expansion Approved by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:45PM CST
Roche (RHHBY) announced that the FDA has approved Avastin in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer.
AGN: 213.37 (+4.17), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27)
Novartis Presents Data on Heart Failure Candidate LCZ696 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:44PM CST
Novartis (NVS) announced new data on pipeline candidate, LCZ696, from the phase III study, PARADIGM-HF.
AGN: 213.37 (+4.17), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27), NVS: 95.58 (+1.20)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), MRK: 59.89 (+0.43), AMGN: 162.24 (+3.10), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27), CELG: 106.78 (+2.42)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 18, 12:25PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Bristol-Myers Squibb Up 12.7% Since SmarTrend Uptrend Call (BMY)
Comtex SmarTrend(R) - Tue Nov 18, 9:31AM CST
SmarTrend identified an Uptrend for Bristol-Myers Squibb (NYSE:BMY) on October 22nd, 2014 at $51.99. In approximately 4 weeks, Bristol-Myers Squibb has returned 12.66% as of today's recent price of $58.57.
BMY: 58.70 (+0.27)
Early Glance: Pharmaceuticals companies
AP - Tue Nov 18, 9:23AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners R&D Solutions to Advance Biopharmaceutical Innovations From Leading U.S. Academic Research Institutions
Business Wire - Tue Nov 18, 1:00AM CST
--Synergy Partners will provide strategic advice and scientific support to Allied-Bristol Life Sciences' R&D efforts.
BMY: 58.70 (+0.27)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 213.37 (+4.17), MRK: 59.89 (+0.43), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 213.37 (+4.17), ACT: 269.60 (+21.66), AMAG: 35.34 (+0.58), BMY: 58.70 (+0.27)
Yearly Dividend Hikes Aren't Always Necessary In A Successful Dividend Growth Portfolio
Willow Street Investments - at Seeking Alpha - Mon Nov 17, 3:41PM CST
SBUX: 77.57 (-0.26), LLY: 67.78 (+0.49), BMY: 58.70 (+0.27), INTC: 34.71 (+0.47)
LabCorp Shows Strength on Covance Buyout Plan, Robust Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 3:34PM CST
On Nov 17, 2014, we issued an updated research report on Laboratory Corporation of America Holdings (LH).
ABC: 89.76 (+0.75), BCR: 167.36 (+2.55), CAH: 81.01 (+0.65), UNH: 98.19 (+1.72), LH: 101.18 (+1.10), BMY: 58.70 (+0.27)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), GERN: 3.17 (+0.19), MRK: 59.89 (+0.43), AZN: 73.98 (+1.48), PFE: 30.59 (+0.27), INCY: 69.64 (-0.06), BMY: 58.70 (+0.27), CTIC: 2.28 (+0.04), NVS: 95.58 (+1.20)
US, German drugmakers team up on cancer medicines
By LINDA A. JOHNSON - AP - Mon Nov 17, 2:51PM CST
TRENTON, N.J. (AP) — Pfizer said Monday that it will partner with German drug and chemical maker Merck in developing potential cancer drugs in a hot new medication class that harnesses the body's immune system to fight cancer.
PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Adexanet Alfa reverses anticoagulant effect of Eliquis in first stage of Phase 3
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:57AM CST
PTLA: 27.29 (+0.43), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update 2014
M2 - Mon Nov 17, 8:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/jmcrhn/targeting_immune) has announced the addition of the "Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update 2014" report to their offering. The Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update is the most up to date and comprehensive pipeline review and competitive assessment you can get on this hot and fast moving area in cancer immunology. There are two sides of immune checkpoint control; those which activate and those which inhibit T-cell activation. the author's Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update covers both sides extensively. There are currently three approved immune check point inhibitors, namely Yervoy (ipilimumab), Keytruda (Pembrolizumab) and Opdivo (nivolumab). Bristol-Myers Squibb's Yervoy, a CTLA4 targeting antibody, was first to be approved in 2011 for the treatment of patients with unresectable or metastatic melanoma. In 2013 world-wide sales on Yervoy alone was close to $1 billion dollars ($960 million). In 2014 came two more approvals, Opdivo was first approved in Japan through Ono Pharmaceutical and later followed by Merck & Co's Keytruda. Both Keytruda and Opdivo are PD-1 inhibitors and were approved for treatment of melanoma. Apart from a quite substantial drug pipeline targeting immune checkpoints in cancer the industry is also highly prolific generating combination therapy agreements with each other, leaving very little on the table for late comers. Drug Pipeline Update at a Glance Investigators Includes more than 59 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies. Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies. Drug name & Synonyms Lists commercial, generic and code names for drugs. Developmental stage This Drug Pipeline Update contains 109 immune checkpoints drugs in development, which have a total of 309 developmental projects in cancer. In addition there are suspended and ceased drugs. Pipeline Breakdown According to Number of Drugs - Marketed# 3 - Pre-registration# 1 - Phase III# 9 - Phase II# 20 - Phase I# 33 - Preclinical# 47 - Suspended# 3 - Ceased# 14 For more information visit http://www.researchandmarkets.com/research/jm...ing_immune
BMY: 58.70 (+0.27)
Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)
GlobeNewswire - Mon Nov 17, 7:18AM CST
-- Andexanet Alfa Rapidly Reversed the Anticoagulant Effect of the Factor Xa Inhibitor Eliquis (apixaban) Among All Study Participants --
PTLA: 27.29 (+0.43), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA)
Business Wire - Mon Nov 17, 7:02AM CST
--Analysis showed treatment with Orencia plus MTX reduced the development of anti-CCP antibodies, an indicator of more severe, persistent, and erosive disease in patients with early rapidly progressing RA
BMY: 58.70 (+0.27)
Global Biologic Therapeutics Market 2014-2018: Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk and Sanofi
M2 - Mon Nov 17, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/tx4gv7/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2014-2018" report to their offering. One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market. According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market. Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Molecule Type 08. Geographical Segmentation 09. Buying Criteria 10. Global Protein Therapeutics Market 11. Global Vaccines Market 12. Global Cell Therapy Market 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Competitive Scenario 20. Market Share Analysis 2013 21. Market Assessment of Major Biologic Therapeutics of Key Vendors 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Abbvie - Amgen - AstraZeneca - Bavarian Nordic - Baxter International - Beijing Minhai Biotechnology - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Biodel - Bristol-Myers Squibb - DiaVacs - Diamyd Medical - Dynavax Technologies - Eli Lilly - F. Hoffmann-La Roche - Generex Biotechnology - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - JN International Medical - Janssen Pharmaceuticals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Tolerion - Vacunas Finlay - XOMA - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/tx...l_biologic
DVAX: 14.67 (+0.21), BAX: 72.58 (+0.58), AMGN: 162.24 (+3.10), LLY: 67.78 (+0.49), BMY: 58.70 (+0.27), SVA: 5.05 (-0.01)
Inovio-Roche End Deal for Development of Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:26PM CST
Inovio Pharmaceuticals, Inc. (INO) announced the termination of its agreement with Roche for the co-development of Inovio's prostate cancer candidate, INO-5150.
INO: 9.86 (-0.07), AZN: 73.98 (+1.48), BMY: 58.70 (+0.27)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Roche's (RHHBY) Avastin Label Expansion Approved by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:45PM CST
Roche (RHHBY) announced that the FDA has approved Avastin in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer.
AGN: 213.37 (+4.17), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27)
Novartis Presents Data on Heart Failure Candidate LCZ696 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:44PM CST
Novartis (NVS) announced new data on pipeline candidate, LCZ696, from the phase III study, PARADIGM-HF.
AGN: 213.37 (+4.17), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27), NVS: 95.58 (+1.20)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), MRK: 59.89 (+0.43), AMGN: 162.24 (+3.10), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27), CELG: 106.78 (+2.42)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 18, 12:25PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Bristol-Myers Squibb Up 12.7% Since SmarTrend Uptrend Call (BMY)
Comtex SmarTrend(R) - Tue Nov 18, 9:31AM CST
SmarTrend identified an Uptrend for Bristol-Myers Squibb (NYSE:BMY) on October 22nd, 2014 at $51.99. In approximately 4 weeks, Bristol-Myers Squibb has returned 12.66% as of today's recent price of $58.57.
BMY: 58.70 (+0.27)
Early Glance: Pharmaceuticals companies
AP - Tue Nov 18, 9:23AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners R&D Solutions to Advance Biopharmaceutical Innovations From Leading U.S. Academic Research Institutions
Business Wire - Tue Nov 18, 1:00AM CST
--Synergy Partners will provide strategic advice and scientific support to Allied-Bristol Life Sciences' R&D efforts.
BMY: 58.70 (+0.27)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 213.37 (+4.17), MRK: 59.89 (+0.43), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 213.37 (+4.17), ACT: 269.60 (+21.66), AMAG: 35.34 (+0.58), BMY: 58.70 (+0.27)
Yearly Dividend Hikes Aren't Always Necessary In A Successful Dividend Growth Portfolio
Willow Street Investments - at Seeking Alpha - Mon Nov 17, 3:41PM CST
SBUX: 77.57 (-0.26), LLY: 67.78 (+0.49), BMY: 58.70 (+0.27), INTC: 34.71 (+0.47)
LabCorp Shows Strength on Covance Buyout Plan, Robust Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 3:34PM CST
On Nov 17, 2014, we issued an updated research report on Laboratory Corporation of America Holdings (LH).
ABC: 89.76 (+0.75), BCR: 167.36 (+2.55), CAH: 81.01 (+0.65), UNH: 98.19 (+1.72), LH: 101.18 (+1.10), BMY: 58.70 (+0.27)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), GERN: 3.17 (+0.19), MRK: 59.89 (+0.43), AZN: 73.98 (+1.48), PFE: 30.59 (+0.27), INCY: 69.64 (-0.06), BMY: 58.70 (+0.27), CTIC: 2.28 (+0.04), NVS: 95.58 (+1.20)
US, German drugmakers team up on cancer medicines
By LINDA A. JOHNSON - AP - Mon Nov 17, 2:51PM CST
TRENTON, N.J. (AP) — Pfizer said Monday that it will partner with German drug and chemical maker Merck in developing potential cancer drugs in a hot new medication class that harnesses the body's immune system to fight cancer.
PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Adexanet Alfa reverses anticoagulant effect of Eliquis in first stage of Phase 3
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:57AM CST
PTLA: 27.29 (+0.43), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update 2014
M2 - Mon Nov 17, 8:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/jmcrhn/targeting_immune) has announced the addition of the "Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update 2014" report to their offering. The Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update is the most up to date and comprehensive pipeline review and competitive assessment you can get on this hot and fast moving area in cancer immunology. There are two sides of immune checkpoint control; those which activate and those which inhibit T-cell activation. the author's Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update covers both sides extensively. There are currently three approved immune check point inhibitors, namely Yervoy (ipilimumab), Keytruda (Pembrolizumab) and Opdivo (nivolumab). Bristol-Myers Squibb's Yervoy, a CTLA4 targeting antibody, was first to be approved in 2011 for the treatment of patients with unresectable or metastatic melanoma. In 2013 world-wide sales on Yervoy alone was close to $1 billion dollars ($960 million). In 2014 came two more approvals, Opdivo was first approved in Japan through Ono Pharmaceutical and later followed by Merck & Co's Keytruda. Both Keytruda and Opdivo are PD-1 inhibitors and were approved for treatment of melanoma. Apart from a quite substantial drug pipeline targeting immune checkpoints in cancer the industry is also highly prolific generating combination therapy agreements with each other, leaving very little on the table for late comers. Drug Pipeline Update at a Glance Investigators Includes more than 59 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies. Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies. Drug name & Synonyms Lists commercial, generic and code names for drugs. Developmental stage This Drug Pipeline Update contains 109 immune checkpoints drugs in development, which have a total of 309 developmental projects in cancer. In addition there are suspended and ceased drugs. Pipeline Breakdown According to Number of Drugs - Marketed# 3 - Pre-registration# 1 - Phase III# 9 - Phase II# 20 - Phase I# 33 - Preclinical# 47 - Suspended# 3 - Ceased# 14 For more information visit http://www.researchandmarkets.com/research/jm...ing_immune
BMY: 58.70 (+0.27)
Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)
GlobeNewswire - Mon Nov 17, 7:18AM CST
-- Andexanet Alfa Rapidly Reversed the Anticoagulant Effect of the Factor Xa Inhibitor Eliquis (apixaban) Among All Study Participants --
PTLA: 27.29 (+0.43), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA)
Business Wire - Mon Nov 17, 7:02AM CST
--Analysis showed treatment with Orencia plus MTX reduced the development of anti-CCP antibodies, an indicator of more severe, persistent, and erosive disease in patients with early rapidly progressing RA
BMY: 58.70 (+0.27)
Global Biologic Therapeutics Market 2014-2018: Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk and Sanofi
M2 - Mon Nov 17, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/tx4gv7/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2014-2018" report to their offering. One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market. According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market. Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Molecule Type 08. Geographical Segmentation 09. Buying Criteria 10. Global Protein Therapeutics Market 11. Global Vaccines Market 12. Global Cell Therapy Market 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Competitive Scenario 20. Market Share Analysis 2013 21. Market Assessment of Major Biologic Therapeutics of Key Vendors 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Abbvie - Amgen - AstraZeneca - Bavarian Nordic - Baxter International - Beijing Minhai Biotechnology - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Biodel - Bristol-Myers Squibb - DiaVacs - Diamyd Medical - Dynavax Technologies - Eli Lilly - F. Hoffmann-La Roche - Generex Biotechnology - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - JN International Medical - Janssen Pharmaceuticals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Tolerion - Vacunas Finlay - XOMA - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/tx...l_biologic
DVAX: 14.67 (+0.21), BAX: 72.58 (+0.58), AMGN: 162.24 (+3.10), LLY: 67.78 (+0.49), BMY: 58.70 (+0.27), SVA: 5.05 (-0.01)
